Loading
MTX-241F is an experimental small molecule from MEKanistic Therapeutics, in preclinical development for glioblastoma, diffuse intrinsic pontine glioma and brain metastases and other cancers.
MTX-241F (MTX-241) is a small molecule (brain-penetrant) from MEKanistic Therapeutics. A brain-penetrant dual PI3K and EGFR inhibitor. Its furthest stage is preclinical development, for glioblastoma, diffuse intrinsic pontine glioma, brain metastases and primary brain tumours. No clinical trial naming it is registered on ClinicalTrials.gov. It has not been shown to work in people.
A brain-penetrant dual PI3K and EGFR inhibitor. Connects to EGFR.
1.MTX-241F slips into a pocket on EGFR.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"MTX-241F" OR ABSTRACT:"MTX-241F" OR TITLE:"MTX-241" OR ABSTRACT:"MTX-241") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MTX-241F, not a curated reading list.
Shares MEKanistic Therapeutics, EGFR and the tag pipeline.
Shares MEKanistic Therapeutics and the tag pipeline.
Shares EGFR and the tag pipeline.
Shares EGFR and the tag pipeline.
Shares EGFR and the tag pipeline.
Shares EGFR and the tag pipeline.
Shares EGFR and the tag pipeline.
Shares EGFR and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/